Jd5efsxtxm8mjatiydls cyclica logo 500 white

CYCLICA - In Silico Drug Discovery Through Proteome-Docking

Toronto Ontario

Cyclica (www.cyclicarx.com) offers a predictive analytics platform, Ligand Express™, which has been extensively used and validated through third-party organizations to develop safer and more efficacious therapeutics. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica is able to offer insight and analysis into your small molecule's effect, in order to augment your drug discovery pipeline and take your asset from bench-to-bedside.

Our Solution

Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology & drug-protein interactomes), evaluates and compares small molecules to predict how each will interact with the human body (i.e. human proteome). Additionally, our in-house database of structurally-characterized bacterial and viral proteomes provide further... Show more »

Cyclica (www.cyclicarx.com) offers a predictive analytics platform, Ligand Express™, which has been extensively used and validated through third-party organizations to develop safer and more efficacious therapeutics. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica is able to offer insight and analysis into your small molecule's effect, in order to augment your drug discovery pipeline and take your asset from bench-to-bedside.

Our Solution

Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology & drug-protein interactomes), evaluates and compares small molecules to predict how each will interact with the human body (i.e. human proteome). Additionally, our in-house database of structurally-characterized bacterial and viral proteomes provide further insight into how your drug will affect certain disease states.

Customer Use Cases

  • Drug Target Identification (Mechanism-of-Action)
  • Drug Repurposing (New Indications)
  • Lead Prioritization (Best Candidate)
  • Adverse Effect Elucidation (Toxicity Profiling)

For more information, please visit www.cyclicarx.com.

« Show less

CYCLICA - In Silico Drug Discovery Through Proteome-Docking has not listed any services.

Computational Drug Target Identification
Price on request
  • Discover the mechanism-of-action for your query compound(s).

Often, a compound is known to have an effect, but the target and mechanism-of-action are not known. This can occur with natural compounds, or with hits from a phenotypical screen. Proteome binding profiles predict not only which proteins your drug or compound is... Show more »

  • Discover the mechanism-of-action for your query compound(s).

Often, a compound is known to have an effect, but the target and mechanism-of-action are not known. This can occur with natural compounds, or with hits from a phenotypical screen. Proteome binding profiles predict not only which proteins your drug or compound is likely to interact with, but also where on the surface of each protein (i.e. which amino acids) the interaction can be found. This information combines with bioassay output to identify the protein target(s) responsible for your new drug or compound’s biological activity. With Ligand Express™, Cyclica is even able to examine protein pathways, granting insights into mechanisms behind symptoms in the body.

STRATEGY: Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology discovery platform), evaluates compounds to understand how each interacts with the human body.

DELIVERABLES: The Computational Output (curated data from PROBEx, SWITCHx & DIVEx) as well as a comprehensive and publication-quality Scientific Report will be provided.
 
OUTCOME: Discovery of each compound's mechanism-of-action, in order to facilitate subsequent in vitro validation and drug development.

TIMELINE: From submission of compounds to delivery of the final report, 40 business days will be required.

« Show less
Computational Drug Repositioning
Price on request
  • Identify new uses for your query compound(s) & shelved asset(s).

Drugs with established targets and FDA approval are becoming a major source of new treatments for other diseases. Proteome binding profiles makes it possible to verify known targets as well as identify additional proteins that may be of clinical interest.... Show more »

  • Identify new uses for your query compound(s) & shelved asset(s).

Drugs with established targets and FDA approval are becoming a major source of new treatments for other diseases. Proteome binding profiles makes it possible to verify known targets as well as identify additional proteins that may be of clinical interest. With its integrated systems biology, Ligand Express™ can highlight novel disease associations for approved drugs. Further analysis into potential targets can help direct exploration into new diseases.

STRATEGY: Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology discovery platform), evaluates compounds to understand how each interacts with the human body.

DELIVERABLES: The Computational Output (curated data from PROBEx, SWITCHx & DIVEx) as well as a comprehensive and publication-quality Scientific Report will be provided.
 
OUTCOME: Identification of repurposing opportunities for each compound, in order to facilitate subsequent in vitro validation and drug development.

TIMELINE: From submission of compounds to delivery of the final report, 40 business days will be required.

« Show less
Computational Lead Optimization
Price on request
  • Determine the best candidate among your query compounds.

Early in the drug development process, decisions have to be made which “lead“ compounds to advance further down the pipeline. These decisions are critical, as any failures down the line will lead to large write-offs in investment. The Ligand Express™ platform produces a... Show more »

  • Determine the best candidate among your query compounds.

Early in the drug development process, decisions have to be made which “lead“ compounds to advance further down the pipeline. These decisions are critical, as any failures down the line will lead to large write-offs in investment. The Ligand Express™ platform produces a unique proteome binding profile for every compound it screens. Each proteome binding profile coupled with the associated systems biology analysis provides distinguishing features of all evaluated compounds. Comparing these key features between leads can help you determine which molecules to prioritize and which may prove problematic. Additionally, Cyclica can provide a more robust analysis that better characterizes the most promising candidates.

STRATEGY: Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology discovery platform), evaluates compounds to understand how each interacts with the human body.

DELIVERABLES: The Computational Output (curated data from PROBEx, SWITCHx & DIVEx) as well as a comprehensive and publication-quality Scientific Report will be provided.
 
OUTCOME: Determination of the best candidate compound, in order to facilitate subsequent in vitro validation and drug development.

TIMELINE: From submission of compounds to delivery of the final report, 40 business days will be required.

« Show less
Computational Toxicology
Price on request
  • Anticipate potential toxicity profiles for your query compound(s).

Adverse effects in pre-clinical testing, clinical trials or on the market can bring a drug program to a grinding halt after large investments have been made. It is important to elucidate the mechanism of such adverse events, both for attempts to rescue a... Show more »

  • Anticipate potential toxicity profiles for your query compound(s).

Adverse effects in pre-clinical testing, clinical trials or on the market can bring a drug program to a grinding halt after large investments have been made. It is important to elucidate the mechanism of such adverse events, both for attempts to rescue a compound, and to avoid repeating mistakes in future programs. Testing lead compounds through Ligand Express™ guides researchers in the discovery of the underlying cause of the negative effects that results in drugs failing clinical trials. Chemogenomics data also provides details about other FDA drugs known to interact with identified protein binders, allowing predictions about potential contraindications. Additionally, Cyclica can look even further into this topic, providing recommendations for development.

STRATEGY: Cyclica’s proprietary suite of computational algorithms, Ligand Express™, which is comprised of PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology discovery platform), evaluates compounds to understand how each interacts with the human body.

DELIVERABLES: The Computational Output (curated data from PROBEx, SWITCHx & DIVEx) as well as a comprehensive and publication-quality Scientific Report will be provided.
 
OUTCOME: Anticipation of each compound's potential for toxicity, in order to facilitate subsequent in vitro validation and drug development.

TIMELINE: From submission of compounds to delivery of the final report, 40 business days will be required.

« Show less
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

CYCLICA - In Silico Drug Discovery Through Proteome-Docking has not received any ratings.

Be the first to endorse CYCLICA - In Silico Drug Discovery Through Proteome-Docking

Endorse this lab